Search Result

Results for "

MEK inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	MEK (100) Akt (2) Apoptosis (36) Aryl Hydrocarbon Receptor (1) Aurora Kinase (1) Autophagy (14) Bacterial (1) Bcl-2 Family (1) Beta-secretase (2) c-Fms (1) c-Met/HGFR (1) Calcium Channel (1) CaMK (1) CDK (3) Cholinesterase (ChE) (2) Cyclin G-associated Kinase (GAK) (1) E3 Ligase Ligand-Linker Conjugates (1) EGFR (4) Endogenous Metabolite (6) ERK (30) Estrogen Receptor/ERR (2) Ferroptosis (1) FLT3 (2) Glutathione S-transferase (1) GSK-3 (2) HBV (1) HCV (1) HDAC (2) HIV (3) HSP (1) Influenza Virus (3) Interleukin Related (1) Isotope-Labeled Compounds (3) JAK (2) JNK (1) Ligands for Target Protein for PROTAC (1) Microtubule/Tubulin (1) Mitophagy (4) Mixed Lineage Kinase (1) Molecular Glues (1) mTOR (1) NF-κB (11) P-glycoprotein (1) p38 MAPK (2) Parasite (2) PDGFR (1) PERK (2) Phosphatase (1) PI3K (5) Pim (1) PKC (1) Potassium Channel (1) PROTACs (2) Raf (9) Ras (1) Reactive Oxygen Species (3) SHP2 (1) Sodium Channel (10) Src (1) STAT (1) TGF-beta/Smad (1) Tie (1) TNF Receptor (1) VEGFR (4) YAP (1)
By Research Areas:	Cancer (121) Cardiovascular Disease (11) Infection (3) Inflammation/Immunology (7) Metabolic Disease (4) Neurological Disease (6)

By Targets:

MEK (100)

Akt (2)

Apoptosis (36)

Aryl Hydrocarbon Receptor (1)

Aurora Kinase (1)

Autophagy (14)

Bacterial (1)

Bcl-2 Family (1)

Beta-secretase (2)

c-Fms (1)

c-Met/HGFR (1)

Calcium Channel (1)

CaMK (1)

CDK (3)

Cholinesterase (ChE) (2)

Cyclin G-associated Kinase (GAK) (1)

E3 Ligase Ligand-Linker Conjugates (1)

EGFR (4)

Endogenous Metabolite (6)

ERK (30)

Estrogen Receptor/ERR (2)

Ferroptosis (1)

FLT3 (2)

Glutathione S-transferase (1)

GSK-3 (2)

HBV (1)

HCV (1)

HDAC (2)

HIV (3)

HSP (1)

Influenza Virus (3)

Interleukin Related (1)

Isotope-Labeled Compounds (3)

JAK (2)

JNK (1)

Ligands for Target Protein for PROTAC (1)

Microtubule/Tubulin (1)

Mitophagy (4)

Mixed Lineage Kinase (1)

Molecular Glues (1)

mTOR (1)

NF-κB (11)

P-glycoprotein (1)

p38 MAPK (2)

Parasite (2)

PDGFR (1)

PERK (2)

Phosphatase (1)

PI3K (5)

Pim (1)

PKC (1)

Potassium Channel (1)

PROTACs (2)

Raf (9)

Ras (1)

Reactive Oxygen Species (3)

SHP2 (1)

Sodium Channel (10)

Src (1)

STAT (1)

TGF-beta/Smad (1)

Tie (1)

TNF Receptor (1)

VEGFR (4)

YAP (1)

By Research Areas:

Cancer (121)

Cardiovascular Disease (11)

Infection (3)

Inflammation/Immunology (7)

Metabolic Disease (4)

Neurological Disease (6)

134

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: MEK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12202

**MEK inhibitor** 2 Publications Verification	MEK	Cancer
MEK inhibitor is a potent *MEK* inhibitor with antitumor potency.

HY-15610

GDC-0623 5+ Cited Publications RG 7421; MEK inhibitor 1	MEK Apoptosis	Cancer
GDC-0623 (RG 7421) is a potent, ATP-uncompetitive inhibitor of *MEK1* (K_i=0.13 nM, +ATP), and displays 6-fold weaker potency against HCT116 (KRAS (G13D), EC₅₀=42 nM) versus A375 (BRAF ^V600E, EC₅₀=7 nM).

HY-139638

MEK4 inhibitor-1	MEK	Cancer
MEK4 inhibitor-1 is a novel *MEK4* inhibitor against pancreatic adenocarcinoma with an IC₅₀ value of 61 nM.

HY-139639

MEK4 inhibitor-2	MEK	Cancer
MEK4 inhibitor-2 is a novel *MEK4* inhibitor against pancreatic adenocarcinoma with an IC₅₀ value of 83 nM.

HY-157750

MEK1/C-Raf-IN-1	MEK Raf	Cancer
MEK1/C-Raf-IN-1 (Compound 14d) is a *MEK1/C-Raf* inhibitor with IC₅₀ values of 97 and 23 nM, respectively. MEK1/C-Raf-IN-1 has antitumor activity .

HY-P4133

MEK1 Derived Peptide Inhibitor 1	ERK MEK	Cancer
MEK1 Derived Peptide Inhibitor 1 is a peptide inhibitor. MEK1 Derived Peptide Inhibitor 1 can inhibit the in vitro activation of ERK2 by *MEK1* with an IC₅₀ value of 30 μM. MEK1 Derived Peptide Inhibitor 1 can be used for the research of cell-permeable .

HY-P4136

*Myristoyl-MEK1 Derived Peptide Inhibitor* 1**	ERK	Cancer
Myristoyl-MEK1 Derived Peptide Inhibitor 1 is the myristoylated form of the MEK1 Derived Peptide Inhibitor 1 (HY-P4133). Myristoyl-MEK1 Derived Peptide Inhibitor 1 inhibits ERK activation with an IC₅₀ of 10 μM .

HY-160414

TRX-COBI (R,R)-TRX-COBI; TRX-cobimetinib	MEK	Cancer
TRX-COBI ((R,R)-TRX-COBI; Trx-cobimetinib) is a *MEK* inhibitor targeting TRX fragments based on Fe ²⁺. TRX-COBI has antitumor activity .

HY-163173

TEAD-IN-8	YAP	Cancer
TEAD-IN-8 is a novel TEAD inhibitor, which potently and specifically inhibits TEAD-YAP transcriptional activities. TM2, alone or in combination with MEK inhibitors, exhibits potent antiproliferative effects in YAP-dependent cancer cells .

HY-P5977

STE-MEK1(13) Ste-MPKKKPTPIQLNP-NH₂; ERK Activation inhibitor Peptide	ERK	Cancer
STE-MEK1(13) (Ste-MPKKKPTPIQLNP-NH ) is a cell permeable ERK1/2 inhibitor (IC₅₀: 13-30 μM). STE-MEK1(13) inhibits ERK1/2 phosphorylation .

HY-15496

E6201 ER-806201	MEK FLT3	Cancer
E6201 (ER-806201) is an ATP-competitive dual kinase inhibitor of *MEK1* and FLT3. E6201 inhibits MEK1- induced ERK2 phosphorylation with an IC₅₀ value of 5.2 nM, MKK4-induced JNK phosphorylation with an IC₅₀ value of 91 nM, and MKK6-induced p38 MAPK phosphorylation with an IC₅₀ value of 19 nM. Anti-tumor and anti-psoriasis efficacy .

HY-15202

Binimetinib 25+ Cited Publications MEK162; ARRY-162; ARRY-438162	MEK Autophagy	Cancer
Binimetinib (MEK162) is an oral and selective *MEK1/2* inhibitor. Binimetinib (MEK162) inhibits *MEK* with an IC₅₀ of 12 nM.

HY-145701

MEK1/2-IN-2	MEK	Cancer
MEK1/2-IN-2 is a potent ATP-competitive *MEK1/2* inhibitor and shows equipotent inhibition of WT MEK1/2 and a panel of MEK1/2 mutant cell lines .

HY-14719

RO4987655 5 Publications Verification CH4987655	MEK	Cancer
RO4987655 is an orally active and highly selective *MEK* inhibitor with an IC₅₀ of 5.2 nM for inhibition of *MEK1/MEK2*.

HY-15202R

Binimetinib (Standard)	MEK Autophagy	Cancer
Binimetinib (Standard) is the analytical standard of Binimetinib. This product is intended for research and analytical applications. Binimetinib (MEK162) is an oral and selective *MEK1/2* inhibitor. Binimetinib (MEK162) inhibits *MEK* with an IC₅₀ of 12 nM.

HY-12058

AZD8330 5+ Cited Publications ARRY-424704; ARRY-704	MEK	Cancer
AZD8330 (ARRY-424704) is a potent, uncompetitive *MEK1/MEK2* inhibitor, with an IC₅₀ of 7 nM.

HY-137881

MEK-IN-4	MEK	Inflammation/Immunology Cancer
MEK-IN-4 is a *MEK* inhibitor. MEK-IN-4 can be used for the research of inflammatory disorders and cancers .

HY-153445A

MEK-IN-6 hydrate	MEK	Cancer
MEK-IN-6 hydrate (compound 69) is a *MEK* inhibitor. MEK-IN-6 hydrate has an IC₅₀ of 2 nM for A375 cells .

HY-132844

Tunlametinib HL-085	MEK	Cancer
Tunlametinib, an antineoplastic agent, is a MEK1/2 inhibitor .

HY-14691

Refametinib 10+ Cited Publications BAY 869766; RDEA119	MEK	Cancer
Refametinib (BAY 869766; RDEA119) is an orally available, potent, non-ATP-competitive, selective, allosteric *MEK1/MEK2* inhibitor with IC₅₀s of 19 nM and 47 nM, respectively.

HY-U00312

MEK-IN-1	MEK	Cancer
MEK-IN-1 is a *MEK* inhibitor extracted from patent WO2008076415A1.

HY-153445

MEK-IN-6	ERK MEK	Cancer
MEK-IN-6 (Example 69) is a *MEK* inhibitor. MEK-IN-6 inhibits ERK1/2 (Thr202/Tyr204) phosphorylation in A375 cells (IC₅₀: 2 nM). MEK-IN-6 can be used for research of cancer .

HY-107622

(E/Z)-BIX02188	Others	Metabolic Disease
(E/Z)-BIX02188 is a MEK5/ERK5 pathway inhibitor. (E/Z)-BIX02188 inhibits the catalytic function of purified MEK5 enzyme.(E/Z)-BIX02188 can be used for the role of MEK5/ERK5 pathway in various biological systems .

HY-50706

Selumetinib 60+ Cited Publications AZD6244; ARRY-142886	MEK Apoptosis	Cancer
Selumetinib (AZD6244) is selective, non-ATP-competitive oral *MEK1/2* inhibitor, with an IC₅₀ of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation.

HY-153864

PROTAC MEK1 Degrader-1	PROTACs MEK ERK	Cancer
PROTAC MEK1 Degrader-1 is a PROTAC targeting *MEK1* with a pIC₅₀ value of 7.0. PROTAC MEK1 Degrader-1 consists of a *MEK1* inhibitor and a von Hippel-Lindau ligand. PROTAC MEK1 Degrader-1 can inhibit ERK1/2 phosphorylation. PROTAC MEK1 Degrader-1 shows an antiproliferative activity against A375 cells .

HY-15437

SL327 5+ Cited Publications	MEK	Cancer
SL327 inhibits *MEK1* and *MEK2, with IC₅₀* values of 180 nM and 220 nM, respectively.

HY-143468

MEK-IN-5	Apoptosis MEK	Cancer
MEK-IN-5 is a potent *MEK* inhibitor and NO donor. MEK-IN-5 significantly reduces the levels of pMEK and pERK in a dose-dependent and time-dependent manner. MEK-IN-5 induces apoptosis in MDA-MB-231 cells .

HY-10999

Trametinib 180+ Cited Publications GSK1120212; JTP-74057	MEK Autophagy Apoptosis	Cancer
Trametinib (GSK1120212; JTP-74057) is an orally active *MEK* inhibitor that inhibits MEK1 and MEK2 with IC₅₀s of about 2 nM. Trametinib activates autophagy and induces apoptosis .

HY-145702

MAP855	MEK ERK	Cancer
MAP855 is a highly potent, selective, ATP-competitive and orally active *MEK1/2* kinase inhibitor (MEK1 ERK2 cascade IC₅₀=3 nM, pERK EC₅₀=5 nM). MAP855 shows equipotent inhibition of wild-type and mutant MEK1/2 .

HY-13064A

Cobimetinib hemifumarate 40+ Cited Publications GDC-0973 hemifumarate; XL-518 hemifumarate	MEK Apoptosis	Cancer
Cobimetinib hemifumarate is a novel selective *MEK1* inhibitor, and the IC₅₀ value against MEK1 is 4.2 nM.

HY-18086

TCS PIM-1 1 4 Publications Verification SC 204330	Pim	Cancer
TCS PIM-1 1 (SC 204330) is a potent, selective and ATP-competitive Pim-1 kianse inhibitor with an IC₅₀ of 50 nM, displays good selectivity over Pim-2 and MEK1/MEK2 (IC₅₀s >20000 nM) .

HY-12042A

Pimasertib hydrochloride AS703026 hydrochloride; MSC1936369B hydrochloride	MEK	Cancer
Pimasertib hydrochloride is a highly selective, ATP non-competitive allosteric orally available *MEK1/2* inhibitor .

HY-164474

DS03090629	MEK	Cancer
DS03090629 is an orally active *MEK* inhibitor that inhibits *MEK* activity in an ATP-competitive manner. DS03090629 exhibits high affinity for both *MEK* and phosphorylated *MEK, with K_d* values of 0.11 and 0.15 nM, respectively. It effectively inhibits the proliferation of BRAF-mutant overexpressing melanoma cell lines, with IC₅₀ values of 74.3 and 97.8 nM for BRAF V600E and MEK1 F53L transfected A375 cells, respectively. DS03090629 holds potential value in the field of anti-melanoma therapy .

HY-50295

CI-1040 20+ Cited Publications PD 184352	MEK Apoptosis	Cancer
CI-1040 (PD 184352) is an orally active, highly specific, small-molecule inhibitor of *MEK* with an IC₅₀ of 17 nM for MEK1.

HY-13064

Cobimetinib 40+ Cited Publications GDC-0973; XL518	MEK Apoptosis	Cancer
Cobimetinib (GDC-0973, RG7420) is a potent, selective and oral *MEK1* inhibitor with an IC₅₀ of 4.2 nM for *MEK1*.

HY-10999S

Trametinib-d4	MEK Autophagy Apoptosis	Cancer
Trametinib-d₄ is the deuterium labeled Trametinib. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib activates autophagy and induces apoptosis[1][2].

HY-12055

BIX02188 3 Publications Verification	MEK ERK	Cancer
BIX02188 is a potent *MEK5*-selective inhibitor with an IC₅₀ of 4.3 nM. BIX02188 inhibits ERK5 catalytic activity, with an IC₅₀ of 810 nM.

HY-10999A

Trametinib (DMSO solvate) 180+ Cited Publications GSK-1120212 (DMSO solvate); JTP-74057 (DMSO solvate)	MEK Apoptosis	Cancer
Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate);JTP-74057 (DMSO solvate)) is an orally active *MEK* inhibitor that inhibits MEK1 and MEK2 with IC₅₀s of about 2 nM. Trametinib (DMSO solvate) activates autophagy and induces apoptosis .

HY-12042

Pimasertib 5+ Cited Publications AS703026; MSC1936369B	MEK	Cancer
Pimasertib (AS703026) is a highly selective, ATP non-competitive allosteric orally available *MEK1/2* inhibitor .

HY-10999S1

Trametinib-13C6	MEK Autophagy Apoptosis	Cancer
Trametinib- ¹³C₆ is the ¹³C-labeled Trametinib. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib activates autophagy and induces apoptosis[1][2].

HY-10999R

Trametinib (Standard)	MEK Autophagy Apoptosis	Cancer
Trametinib (Standard) is the analytical standard of Trametinib. This product is intended for research and analytical applications. Trametinib (GSK1120212; JTP-74057) is an orally active *MEK* inhibitor that inhibits MEK1 and MEK2 with IC₅₀s of about 2 nM. Trametinib activates autophagy and induces apoptosis .

HY-10999S2

Trametinib-13C,d3 GSK1120212-¹³C,d₃; JTP-74057-¹³C,d₃	Isotope-Labeled Compounds MEK Autophagy Apoptosis	Cancer
Trametinib- ¹³C,d₃ is the ¹³C- and deuterium labeled Trametinib. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib activates autophagy and induces apoptosis[1][2].

HY-50706A

Selumetinib sulfate 60+ Cited Publications AZD6244 sulfate; ARRY-142886 sulfate	MEK Apoptosis	Cancer
Selumetinib (AZD6244) is selective, non-ATP-competitive oral MEK1/2* inhibitor,* with an IC₅₀ of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation.

HY-18652

Avutometinib 3 Publications Verification Ro 5126766; CH5126766	MEK Raf	Cancer
Avutometinib (Ro 5126766) is a first-in-class dual *MEK/RAF* inhibitor that allosterically inhibits BRAF ^V600E, CRAF, *MEK, and BRAF* (IC₅₀: 8.2, 56, 160 nM, and 190 nM, respectively).

HY-12031A

U0126 Maximum Cited Publications 366 Publications Verification	MEK Autophagy Mitophagy Influenza Virus	Cancer
U0126 is a potent, non-ATP competitive and selective *MEK1* and *MEK2* inhibitor, with IC₅₀s of 72 nM and 58 nM, respectively. U0126 is an autophagy and mitophagy inhibitor .

HY-13303

RO 4927350	MEK	Cancer
RO 4927350 is a potent and selective non-ATP-competitive MEK1/2 inhibitor. RO 4927350 exhibits significant antitumor efficacy in a broad spectrum of tumor models .

HY-107619

PD-334581	MEK	Cancer
PD-334581 is a *MEK1* inhibitor .

HY-12062

PD318088 1 Publications Verification	MEK	Cancer
PD318088 is a potent, allosteric and non-ATP competitive *MEK1/2* inhibitor, an analog of PD184352 (HY-50295). PD318088 binds simultaneously with ATP in a region of the MEK1 active site that is adjacent to the ATP-binding site. PD318088 can be used for cancer research .

HY-107417

Hypothemycin	VEGFR MEK FLT3 PDGFR ERK	Cancer
Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for VEGFR2/VEGFR1, *MEK1/MEK2, FLT-3, PDGFRβ/PDGFRα, and ERK1/ERK2*, respectively .

HY-107621

U0124	MEK	Cancer
U0124, an inactive U0126 analog, has no effect on c-Fos and c-Jun protein or mRNA levels. U0126 is a MEK inhibitor. U0124 does not inhibit MEK at concentrations up to 100 μM .

Cat. No.	Product Name

HY-L010

MAPK Compound Library

544 compounds

MAPK families play an important role in complex cellular programs like proliferation, differentiation, development, transformation, and apoptosis. In mammalian cells, four MAPK families have been clearly characterized: ERK1/2, C-Jun N-terminal kinse/stress-activated protein kinase (JNK/SAPK) , p38 kinase and ERK5. They respond to different signals. Each MAPK-related cascade consists of three enzymes that are activated in series: a MAPK kinase kinase (MAPKKK), a MAPK kinase (MAPKK) and a MAP kinase (MAPK). MAPK signaling pathways has been implicated in the development of many human diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and various types of cancers.

MCE designs a unique collection of 544 MAPK signaling pathway inhibitors that act as a useful tool for MAPK-related drug screening and disease research.

Cat. No.	Product Name	Type

HY-10254G

Mirdametinib (GMP) PD0325901 (GMP); PD325901 (GMP)	Fluorescent Dye
Mirdametinib (PD0325901) (GMP) is Mirdametinib (HY-10254) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mirdametinib is an orally active, selective and non-ATP-competitive *MEK* inhibitor .

HY-B0185G

Lidocaine (GMP)

Lignocaine (GMP)

Fluorescent Dye

Lidocaine (GMP) is Lidocaine (HY-B0185) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Lidocaine inhibits sodium channels involving complex voltage and using dependence . Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia .

Cat. No.	Product Name	Type

HY-10254G

Mirdametinib (GMP) PD0325901 (GMP); PD325901 (GMP)	Biochemical Assay Reagents
Mirdametinib (PD0325901) (GMP) is Mirdametinib (HY-10254) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mirdametinib is an orally active, selective and non-ATP-competitive *MEK* inhibitor .

HY-B0185G

Lidocaine (GMP)

Lignocaine (GMP)

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area

HY-P4133

MEK1 Derived Peptide Inhibitor 1	ERK MEK	Cancer
MEK1 Derived Peptide Inhibitor 1 is a peptide inhibitor. MEK1 Derived Peptide Inhibitor 1 can inhibit the in vitro activation of ERK2 by *MEK1* with an IC₅₀ value of 30 μM. MEK1 Derived Peptide Inhibitor 1 can be used for the research of cell-permeable .

HY-P4136

*Myristoyl-MEK1 Derived Peptide Inhibitor* 1**	ERK	Cancer
Myristoyl-MEK1 Derived Peptide Inhibitor 1 is the myristoylated form of the MEK1 Derived Peptide Inhibitor 1 (HY-P4133). Myristoyl-MEK1 Derived Peptide Inhibitor 1 inhibits ERK activation with an IC₅₀ of 10 μM .

HY-P5977

STE-MEK1(13) Ste-MPKKKPTPIQLNP-NH₂; ERK Activation inhibitor Peptide	ERK	Cancer
STE-MEK1(13) (Ste-MPKKKPTPIQLNP-NH ) is a cell permeable ERK1/2 inhibitor (IC₅₀: 13-30 μM). STE-MEK1(13) inhibits ERK1/2 phosphorylation .

HY-P10074

TAT-MEK1	ERK	Inflammation/Immunology
TAT-MEK1 is an inhibitor ofERK2, consisting of TAT and MEK1 (N-terminal), TAT (YGRKKRRQRRR) derived from human immunodeficiency (HIV-1) transcriptional trans activator (TAT), is a cell-penetrating peptide. TAT-MEK1 IC₅₀ in vitro for ERK2 is 29 μM .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-107417

Hypothemycin	Structural Classification Monophenols Microorganisms Antifungal Macrolide Antibiotics Classification of Application Fields Antibiotics Source classification Phenols Disease Research Disease Research Fields Cancer	VEGFR MEK FLT3 PDGFR ERK
Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for VEGFR2/VEGFR1, *MEK1/MEK2, FLT-3, PDGFRβ/PDGFRα, and ERK1/ERK2*, respectively .

HY-19700

trans-Zeatin 1 Publications Verification	Structural Classification Natural Products Zea mays L. Classification of Application Fields Source classification Plants Endogenous metabolite Cytokinin Agricultural Research Gramineae Other Diseases Phytohormone Disease Research Fields	MEK ERK Endogenous Metabolite
trans-Zeatin is a plant cytokinin, which plays an important role in cell growth, differentiation, and division; trans-Zeatin also inhibits UV-induced *MEK/ERK* activation.

HY-14590

Kaempferol Maximum Cited Publications 35 Publications Verification Kempferol; Robigenin	Flavonols Structural Classification Classification of Application Fields Anti-aging Source classification Plants Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Microorganisms other families Sunscreen Phenols Polyphenols Cosmetic Research Disease Research Fields Cancer	Estrogen Receptor/ERR Autophagy Mitophagy Apoptosis HIV Parasite Endogenous Metabolite
Kaempferol (Kempferol), a flavonoid found in many edible plants, inhibits estrogen receptor α expression in breast cancer cells and induces apoptosis in glioblastoma cells and lung cancer cells by activation of MEK-MAPK. Kaempferol can be uesd for the research of breast cancer .

HY-108635

C16-PAF 10+ Cited Publications PAF (C16)	Structural Classification Natural Products Human Gut Microbiota Metabolites Classification of Application Fields Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	p38 MAPK MEK ERK Endogenous Metabolite
C16-PAF (PAF (C16)), a phospholipid mediator, is a platelet-activating factor and ligand for PAF G-protein-coupled receptor (PAFR). C16-PAF exhibits anti-apoptotic effect and inhibits caspase-dependent death by activating the PAFR. C16-PAF is a potent MAPK and *MEK/ERK* activator. C16-PAF induces increased vascular permeability .

HY-N0226A

Epiberberine chloride 4 Publications Verification	Alkaloids Structural Classification Neurological Disease Classification of Application Fields Coptis chinensis Franch. Ranunculaceae Source classification Metabolic Disease Plants Isoquinoline Alkaloids Disease Research Fields	Cholinesterase (ChE) Beta-secretase Reactive Oxygen Species
Epiberberine chloride is an alkaloid isolated from Coptis chinensis, acts as a potent AChE and BChE inhibitor, and a non-competitive BACE1 inhibitor, with IC₅₀s of 1.07, 6.03 and 8.55 μM, respectively. Epiberberine chloride has antioxidant activity, with peroxynitrite ONOO ^- scavenging effect (IC₅₀, 16.83 μM), and may protect against Alzheimer disease . Epiberberine chloride inhibits the early stage of differentiation of 3T3-L1 preadipocytes, downregulates the Raf/MEK1/2/ERK1/2 and AMPKα/Akt pathways . Epiberberine has the potential effect in the research of diabetic disease .

HY-N12740

Napyradiomycin B4	Structural Classification Natural Products Microorganisms Source classification	MEK ERK
Napyradiomycin B4 is a Napyradiomycin derivative, which inhibits the RANKL-induced *MEK-ERK* signaling pathway. Napyradiomycin B4 attenuates osteoclastogenesis and prevents alveolar bone destruction in experimental periodontitis .

HY-W065835

2-Bromoaldisine	Structural Classification Alkaloids Pyrrole Alkaloids Marine natural products Source classification	HIV
2-Bromoaldisine is a pyrrole alkaloid that can be isolated from the Red Sea: marine sponge Stylissa carter. 2-Bromoaldisine inhibits HIV-1 vector infection. 2-Bromoaldisine inhibits *Raf/MEK/MAPK* pathway .

HY-14590R

Kaempferol (Standard) Kempferol(Standard); Robigenin (Standard)	Structural Classification Classification of Application Fields Anti-aging Source classification Plants Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids other families Sunscreen Phenols Cosmetic Research Disease Research Fields Cancer	Estrogen Receptor/ERR Autophagy Mitophagy Apoptosis HIV Parasite Endogenous Metabolite
Kaempferol (Standard) is the analytical standard of Kaempferol. This product is intended for research and analytical applications. Kaempferol (Kempferol), a flavonoid found in many edible plants, inhibits estrogen receptor α expression in breast cancer cells and induces apoptosis in glioblastoma cells and lung cancer cells by activation of MEK-MAPK. Kaempferol can be uesd for the research of breast cancer .

HY-N0226

Epiberberine	Alkaloids Source classification Ranunculaceae Coptis chinensis Franch. Plants Isoquinoline Alkaloids	Cholinesterase (ChE) Beta-secretase
Epiberberine is an alkaloid isolated from Coptis chinensis, acts as a potent AChE and BChE inhibitor, and a non-competitive BACE1 inhibitor, with IC₅₀s of 1.07, 6.03 and 8.55 μM, respectively. Epiberberine has antioxidant activity, with peroxynitrite ONOO ^- scavenging effect (IC₅₀, 16.83 μM), and can be used for the research of Alzheimer disease . Epiberberine inhibits the early stage of differentiation of 3T3-L1 preadipocytes, downregulates the Raf/MEK1/2/ERK1/2 and AMPKα/Akt pathways . Epiberberinecan be used for the research of diabetic disease .

Cat. No.	Product Name	Chemical Structure

HY-19700S

trans-Zeatin-d5
trans-Zeatin-d₅ is deuterium labeled trans-Zeatin. trans-Zeatin is a plant cytokinin, which plays an important role in cell growth, differentiation, and division; trans-Zeatin also inhibits UV-induced MEK/ERK activation.

HY-B0185AS

Lidocaine-d10 hydrochloride

Lidocaine-d₁₀ (hydrochloride) is the deuterium labeled Lidocaine hydrochloride. Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride, an amide derivative, has the potential for the research of the ventricular arrhythmia[2].

HY-B0185S1

Lidocaine-d10

Lidocaine-d₁₀ is the deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia[2].

HY-10999S

Trametinib-d4
Trametinib-d₄ is the deuterium labeled Trametinib. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib activates autophagy and induces apoptosis[1][2].

HY-10999S1

Trametinib-13C6
Trametinib- ¹³C₆ is the ¹³C-labeled Trametinib. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib activates autophagy and induces apoptosis[1][2].

HY-10999S2

Trametinib-13C,d3
Trametinib- ¹³C,d₃ is the ¹³C- and deuterium labeled Trametinib. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib activates autophagy and induces apoptosis[1][2].

HY-13064S1

Cobimetinib-d4 hydrochloride
Cobimetinib-d₄ hydrochloride is deuterated labeled Cobimetinib (HY-13064). Cobimetinib (GDC-0973, RG7420) is a potent, selective and oral *MEK1* inhibitor with an IC₅₀ of 4.2 nM for *MEK1*.

HY-13078S

Cobimetinib-13C6 racemate
Cobimetinib- ¹³C₆ (GDC-0973- ¹³C₆; XL518- ¹³C₆) racemateis the deuterium labeledCobimetinib (racemate)(HY-13078) . Cobimetinib racemate (GDC-0973 racemate; XL518 racemate) is the racemate of Cobimetinib. Cobimetinib is a potent and selective MEK inhibitor .

HY-B0185AS1

Lidocaine-d6 hydrochloride

Lidocaine-d₆ (hydrochloride) is deuterium labeled Lidocaine (hydrochloride). Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride is an amide derivative and a agent to treat ventricular arrhythmia and an effective tumor-inhibitor[2].

HY-B0185S

Lidocaine-d10 N-Oxide

N-Oxide Lidocaine-d₁₀ is the deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia[2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

MEK inhibitor

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products